Abbvie Inc (NYSE:ABBV) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) have announced an exclusive global license and option agreement for Alpine’s best in class dual ICOS/CD28 costimulation antagonist, ALPN-101.
AbbVie to co-develop ALPN-101 with Alpine
ICOS and CD28 are important costimulatory molecules playing critical roles in inflammatory autoimmune diseases. Alpine’s ALPN-101 is a potent ICOS and CD28 pathway inhibitor that has shown significant efficacy in several preclinical disease simulations. It demonstrated favorable tolerability and safety, as well as pharmacodynamics and pharmacokinetics; in first human studies in healthy counters.
Tom Hudson, the chief scientific officer of AbbVie, indicated that the company’s immunology expertise has resulted in incredible breakthroughs in autoimmune disease treatment. Hudson indicated that the double mechanism of action of ALPN-101 has the massive potential of being the next-generation systemic lupus erythematosus and other multiple autoimmune diseases treatment.
As per the terms of the agreement, Alpine is expected to receive a $60 million upfront payment and will receive up to $805 million. This is for exercising the options and depending on future development, regulatory, and commercial milestones. After exercising the option, AbbVie will be the cone to carry clinical development, production as well as commercialization of ALPN-101.
AbbVie’s upadacitinib monotherapy demonstrate skin clearance improvement
The company also recently announced that its upadacitinib monotherapy (15mg and 30mg per day) met primary endpoints or around 75% improvement in the Eczema Area Severity Index. It also includes the Investigator’s Global Assessment for Atopic Dermatitis of almost clear or clear after 16 weeks in adolescents and adults with moderate to chronic atopic dermatitis. This is for systemic therapy candidates with the pivotal third phase study being the first study evaluating RINVOQ’s safety and efficacy in moderate to severe atopic dermatitis treatment.
Those patients in the study that received either 15mg or 30mg upadacitinib monotherapy demonstrated considerable skin clearance improvements. Out of the total patients, 70%/80% attained EASI 75 after 16 weeks compared to 16% on the control group. Equally, those that received upadacitinib 15mg/30mg also achieved 48%/62% vIGA-AD 0/1 compared to 8% in the control group.